Tag:
inhaled medicines
Latest Headlines
Latest Headlines
Discovery Labs targets late 2012 launch of Afectair ventilator drug delivery
Discovery Labs ($DSCO) envisions a late 2012 commercial launch in both the U.S. and Europe of its Afectair ventilator drug delivery system, assuming manufacturing timelines stick and European
Alexza's Adasuve slapped with delayed FDA review
The FDA slammed Alexza Pharmaceuticals ( $ALXA ) with another setback this week in its drive to bring the antipsychotic drug Adasuve to market. Regulators are extending by three months their review of
Civitas' inhaled L-dopa Parkinson's treatment passes Phase I
Civitas Therapeutics generated positive top line results in a Phase I trial of CVT-301, its inhaled version of L-dopa to treat Parkinson's disease-related tremors. The drug, which is ingested through
UPDATED: FDA panel recommends approving Alexza's inhaled antipsychotic in split vote
An FDA panel of experts recommended approval for Alexza Pharmaceuticals' ( $ALXA ) inhaled, fast-acting antipsychotic drug Adasuve, as long as the company limits the dose to once a day and follows
Mylan to acquire Pfizer respiratory tech for $17.5M
Mylan ($MYL) will pay $17.5 million to acquire global development, manufacturing and commercialization rights to Pfizer's dry powder respiratory drug delivery system. Pending regulatory...
SkyePharma hit with European delay on Flutiform app
SkyePharma's troubles persisted with its combo asthma product Flutiform, with European regulators unable to meet the drug-delivery specialist's approval timeline. Investors reacted to the news and
Novartis sees low-dose Neohaler approval as important step
The once-daily Arcapta Neohaler by Novartis has been approved by the FDA for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary
Mist inhaler to treat lung disease may not be safe
A combination of a bad drug-delivery device and a drug with serious side-effects for patients with heart problems has researchers at Johns Hopkins warning against the use of mist inhalers to treat
MAP Pharma files NDA for orally inhaled migraine treatment
Those who suffer from migraines, and cannot find relief from traditional oral medication, might soon have another choice with an orally inhaled migraine drug. MAP Pharmaceuticals, a 2008 Emerging
More than one way to produce particles for inhaled drug delivery
PharmTech.com has an in-depth report on alternate ways of producing inhalable drug particles, the preferred method of drug delivery to the lungs. For decades, the industry standard has been
